Atilmotin

Summary

Atilmotin is a synthetic motilin receptor agonist peptide developed as a prokinetic agent for gastroparesis and related gastric motility disorders. It was investigated as an alternative to erythromycin-based motilin agonists with potentially improved receptor selectivity and reduced tachyphylaxis.

Mechanism of Action

Selectively activates motilin receptors (MLN1) in the gastrointestinal tract, stimulating coordinated antral and duodenal contractions to accelerate gastric emptying and promote gastrointestinal motility

Routes of Administration

Goals & Uses

• Gastroparesis treatmentGastrointestinal MotilityModerate
• Postoperative ileus preventionGastrointestinal MotilityLow
• Gastroesophageal refluxGastrointestinal MotilityLow

Contraindications

• Known hypersensitivity to atilmotin or motilin analoguesAllergyHigh
• Gastrointestinal obstructionStructural GI DisorderHigh

Adverse Effects

• Injection site reactionsLocalCommon
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• TachyphylaxisPharmacodynamicUncommon
• DiarrheaGastrointestinalUncommonLoose or frequent stools
• Abdominal crampingGastrointestinalCommon

Drug Interactions

• Anticholinergic agentsModerate
• Opioid analgesicsModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Severe renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative

Regulatory Status

• European UnionInvestigationalNo marketing authorisation granted; early-phase studies conducted
• United StatesInvestigationalInvestigated under IND; no approved indication; development status uncertain
• United KingdomUnknownNo known regulatory submission or approval

Atilmotin has not received regulatory approval in any major jurisdiction. Development was conducted primarily in preclinical and early clinical research settings; no NDA or MAA filing is known to have been completed.

Evidence & Sources

No sources recorded yet.